Search

Displaying results 2341 - 2350 of 10000 in total
  1. Drug

    1,1,1,3,3,3-HEXAFLUORO-2-{4-[(2,2,2-TRIFLUOROETHYL)AMINO]PHENYL}PROPAN-2-OL

    go.drugbank.com/drugs/DB07082
    Experimental

    Synonyms: 1,1,1,3,3,3-HEXAFLUORO-2-{4-[(2,2,2-TRIFLUOROETHYL)AMINO]PHENYL}PROPAN-2-OL
  2. Drug

    2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine

    go.drugbank.com/drugs/DB07267
    Experimental

    Synonyms: 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
  3. Drug

    Cephalosporin C

    go.drugbank.com/drugs/DB03313
    Experimental

    Synonyms: 7-(5-Amino-5-carboxyvaleramido)cephalosporanic acid, Cephalosporin CCategories: Heterocyclic Compounds, 2-Ring
  4. Drug

    1-{[1-(2-AMINO-3-PHENYL-PROPIONYL)-PYRROLIDINE-2-CARBONYL]-AMINO}-2-(3-CYANO-PHENYL)-ETHANEBORONIC ACID

    go.drugbank.com/drugs/DB08420
    Experimental

    Synonyms: 1-{[1-(2-AMINO-3-PHENYL-PROPIONYL)-PYRROLIDINE-2-CARBONYL]-AMINO}-2-(3-CYANO-PHENYL)-ETHANEBORONIC ACID
  5. Drug

    5-Alpha-Androstane-3-Beta,17beta-Diol

    go.drugbank.com/drugs/DB03882
    Experimental

  6. Drug

    N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine

    go.drugbank.com/drugs/DB03144
    Experimental

    Synonyms: N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine, N-omega-hydroxy-L-arginine
  7. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
  8. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.

    Synonyms: 1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-ureaCategories: Heterocyclic Compounds, 2-Ring
  9. Drug

    VPO-227

    go.drugbank.com/drugs/DB18004
    Experimental

    Synonyms: (+-)-9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid
  10. Drug

    Miransertib

    go.drugbank.com/drugs/DB14982
    Investigational

    Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).

    Synonyms: 3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}pyridin-2-amineCategories: Heterocyclic Compounds, 1-Ring